Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prochlorperazine inhalation
- Development stage
- Discontinued
- Lead developer
- Ferrer
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Inhaled PCZ 10 mg is the 10 mg dose of Staccato Prochlorperazine (AZ-001), an inhaled formulation of the dopamine D2 receptor antagonist prochlorperazine. It was originally developed by Alexza Pharmaceuticals and later acquired by Nova Pneuma, a subsidiary of Lee's Pharmaceutical. The drug is designed for the acute treatment of migraine headaches and is delivered via the proprietary Staccato system—a hand-held, single-dose inhaler that vaporizes unformulated drug into a condensation aerosol for rapid deep lung delivery, producing intravenous-like pharmacokinetics. AZ-001 completed Phase 2b clinical development for acute migraine, demonstrating significant 2-hour pain relief, but development was subsequently discontinued.
- Brand names
- Staccato
- Other names
- Inhaled PCZInhaled PCZ 10 mgInhaled prochlorperazineStaccato prochlorperazine
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)HTR6 (5-hydroxytryptamine receptor 6)ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DAT (Dopamine plasma membrane transport protein)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)P2RX7 (P2X purinoceptor 7)
Beyond the preview
Go deeper on prochlorperazine inhalation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prochlorperazine inhalation.